Advisory Board

Home / Team / Advisory Board

Olga Krylova

  • Director of Business Development, Otsuka Europe.
  • Worked as a scientist at the leading research centers in the UK (UCL, Imperial College) and in the industry (at Glaxosmithkline), later joining Mitsui&Co as a senior BD&L analyst.
  • In 2011 joined Pfizer as Senior Director, Emerging Science & Innovation, where she was responsible for scientific cooperation in Russia, Eastern Europe and Israel. Since 2016, was responsible for Pfizer’s scientific research and development partnerships in the UK.

 

Vitaly Proutski

  • Former head of R&D in Russia and Eastern Europe and head of R&D bioinformatics support, AstraZeneca
  • 15+ years of experience in Bio-IT (EU, Great Britain)

Alexey Lugovskoy

Dmitry Samarsky

  • CTO at Sirnaomics, ex-CSO at Silence Therapeutics
  • distinguished editor at Journal of RNAi & Gene Silencing
  • 20+ years of experience (R&D, business development, sales) in the USA and developing countries

Yan Lavrovsky

  • CEO and CSO, R-Pharm Overseas, Inc (USA)
  • Held senior positions in Avineuro Pharmaceuticals, Inc., ChemDiv, Inc. and Serono, Geneva, Switzerland and Boston, Massachusetts

Valeria Povolotski

  • Vice-president of R-Pharm Overseas, Inc (USA)
  • 15+ years of experience in drug development and 10+ years of experience in business development (licensing, M&A and venture investments)

Mikhail Samsonov

  • Medical director, R-Pharm
  • More than 17 years of experience in BMS and Novartis on various senior and executive positions in clinical development and medical questions

Evgeny Sverdlov

  • Former director of Institute of Molecular Genetics of the Russian Academy of Sciences (IBCh RAS), leading scientific organization in the field of molecular biology in Russia.
  • One of the most quoted biologists in Russia, department head in IBCh RAS and IMG RAS

Alexander Gabibov

  • Professor, Full Member of the Russian Academy of Sciences, biochemist, molecular biologist, Director of the Institute of Bioorganic Chemistry of the Russian Academy of Sciences.
  • His research in the fiels of biocatalysis, immunochemistry, autoimmune neurodegenerative diseases, personalized medicine, combinatorial approaches are achnowledged all over the world.

Sergei Petukhov

  • Joined RBV in 2018, transiting from being a Partner of Enso Ventures where he led biotechnology investments
  • Held Board positions at Enso portfolio companies including Seres, Cavion, Galera, Axcella, NeuroVia, and Cellectar Biosciences
  • Prior to Enso, Dr. Petukhov worked at several investment firms in Great Britain, the US and Russia